Anthropic’s $1.5B AI Venture with Wall Street Firms Targets Private Equity Market 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
GameStop Proposes $56 Billion eBay Acquisition in Bold Strategic Move 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
NAB First-Half Earnings Miss Forecasts Amid Rising Global Risks 
Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
LAKE FOREST, Ill., May 07, 2018 -- Depomed, Inc. (NASDAQ:DEPO) today announced that members of senior management will participate at the 2018 UBS Global Healthcare Conference in a session scheduled for 1:30 pm ET on Tuesday, May 22, 2018 in New York, NY.
This presentation will be webcast and can be accessed via the Investor Relations page of the Depomed website at www.depomed.com. A recording of the webcasts will be archived for 30 days.
About Depomed
Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need. Depomed currently markets three medicines focused on neuropathic pain and migraine through its Neurology and Pain businesses and its emerging Orphan Specialty Business is focused on orphan drug indications and areas of unmet medical need. To learn more about Depomed, visit www.depomed.com.
INVESTOR AND MEDIA CONTACTS:
John B. Thomas
SVP, Investor Relations and Corporate Communications
[email protected]
